Analyst predicts blockbuster potential for Biomarin's growth hormone
The US-based biotech company Biomarin is edging closer to the launch of dwarfism drug Voxzogo and one analyst sees signs of a potential blockbuster. The US Food and Drug Administration is expected to reach a decision this week.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
Within the week, Biomarin will know whether it has received the green light to market Voxzogo – its treatment for achondroplasia, also known as dwarfism – from the US Food and Drug Administration (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
